Complex Medicines: 
Understanding the Interplay with Biological Systems

25 May 2021  |  2 - 3PM BST

The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs.

© Medicines Discovery Catapult 2021. All rights reserved. Read our Privacy Policy


The early assessment of prototype nanomedicine nano-bio interactions - Zahra Rattray (University of Strathclyde)
The interaction of colloidal gene delivery vehicles with model biomembranes - Jayne Lawrence (The University of Manchester)
The challenges of determining drug levels and PK profiles for complex drug modalities - Robert Wheller (LGC)




Complex Medicines: Understanding Safety & Efficacy
15 June 2021  |  2 - 3PM BST
Watch the recording >

Complex Medicines: Selection and Characterisation of the Lead
18 May 2021  |  2 - 3PM BST
Watch the recording >

Complex Medicines: Ready for the Clinic/Scaling up for Success
22 June 2021  |  2 - 3PM BST
Watch the recording >

Complex Medicines: A Glance at Novel Drug Delivery Systems
8 June 2021  |  2 - 3PM BST
Watch the recording >

Complex Medicines: Why, What, When? Opportunities and Challenges
11 May 2021  |  2 - 3PM BST
Watch the recording >

Dr Sarah Brockbank
Sarah Brockbank is Lead Scientist of External Drug Discovery at the Medicines Discovery Catapult. Here she supports SMEs develop and execute drug discovery projects and provides the project management of virtual preclinical programmes by connecting clients with expertise and capabilities.

Sarah has 30 years’ experience in the pharmaceutical industry. She is a molecular biologist with a focus mainly in target identification & validation and has worked across a broad range of disease areas. Sarah was a Drug Discovery Project Leader at AstraZeneca and she also has extensive experience in collaboration management and project management of large public-private consortia.

What can be learnt from traditional lead optimisation campaigns? Here we consider how to turn a lead in to a molecule with potential to be a medicine.

Dr Zahra Rattray
Zahra Rattray is an interdisciplinary translational pharmaceutical scientist with over 10 years’ experience of working in the academic, industry and clinic sectors developing a diverse molecule portfolio. Zahra received her PhD in Drug Delivery from the University of Manchester in 2013, and completed a postdoctoral research position at Manchester, developing new analytical pipelines for profiling antibody drug product stability.

Zahra has significant formulation experience from her time at AstraZeneca Pharmaceuticals as both a pre-clinical and late-stage formulation scientist. Zahra completed a postdoctoral research position at the Yale School of Medicine in partnership with Patrys Ltd where she explored cell-penetrating autoantibodies as DNA damage repair agents for the treatment of glioblastoma, and as targeting ligands for drug and gene delivery systems. She is currently a Chancellor’s Research Fellow at the University of Strathclyde where her team explores the development of bioanalytical measurements for profiling the nanoparticle protein corona, and the role of nuclear import in cancer progression.

Robert Wheller
Robert Wheller worked in the field of bioanalysis for the last 16 years, starting his career within the DMPK group at GSK, gaining experience in small molecule, oligonucleotide and protein quantitation using LC-MS/MS and LBA techniques. He have since moved to LGC where as a principal scientist led a team of scientists performing protein LC-MS/MS bioanalysis, providing technical oversight for these challenging assays.  Robert's latest role as associate scientific director focusses on supporting the wider LC-MS/MS bioanalytical group, ensuring the scientific rigour of methods that are developed, directing research projects aligned with the departmental strategy and building external reputation.

Jayne Lawrence
Jayne is currently Head of the Division of Pharmacy and Optometry, Manchester University. Over the past 25 years she has pioneered the use of neutron scattering techniques in pharmaceutical science. Before then, with the exception of neutron crystallography, neutron scattering was not used in the pharmaceutical science community, whereas now it is gaining an increasing acceptance amongst both pharmacy academics and pharmaceutical industrialists as being an invaluable tool in answering a range of important pharmaceutical questions – questions that cannot be answered by any other technique currently available. For example, Jayne has successfully used neutron diffraction to elucidate the organization of lipids in models of the stratum corneum of human skin and as a means to understand the selectivity of the antifungal drug, amphotericin B, towards fungal vs. mammalian membranes. Jayne’s use of small angle neutron scattering has helped in the formulation of microemulsions with enhanced drug solubilizing capacity and furnished an explanation as to how polymers help to stabilize drug nanoparticles Most relevant for this webinar is how neutron reflectivity has been invaluable in helping to determine how gene delivery vehicles and the nucleic acid they contain interact with cell and endosomal membranes thereby aiding the design of improved gene delivery vehicles.


This webinar has already taken place. Watch a recording and view the slides on our website >